Filing Details
- Accession Number:
- 0001179110-18-008611
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-06-15 16:16:56
- Reporting Period:
- 2018-06-13
- Accepted Time:
- 2018-06-15 16:16:56
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1650664 | Editas Medicine Inc. | EDIT | Biological Products, (No Disgnostic Substances) (2836) | 464097528 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1682323 | Charles Albright | C/O Editas Medicine, Inc. 11 Hurley St. Cambridge MA 02141 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-06-13 | 10,000 | $16.51 | 10,000 | No | 4 | M | Direct | |
Common Stock | Disposition | 2018-06-13 | 10,000 | $35.98 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2018-06-13 | 10,000 | $0.00 | 10,000 | $16.51 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
205,000 | 2026-09-08 | No | 4 | M | Direct |
Footnotes
- The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 23, 2018.
- This transaction was executed in multiple trades at prices ranging from $35.62 to $36.60. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This option was granted on September 9, 2016 and is scheduled to vest over four years with 25% of the shares having vested on August 22, 2017, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through August 22, 2020.